The Pharmacy Times® Migraine Resource Center is a comprehensive resource for clinical news and expert insights on treatments for migraine headaches, which can cause severe throbbing pain or a pulsing sensation.
February 1st 2023
Patients with acute migraines should assess their condition before starting a treatment regimen.
Novel Migraine Treatment Shows Mixed Results in Phase 3 Efficacy Trial
November 16th 2022Investigational migraine drug produces significant effects on both freedom-from-pain and MBS-free endpoints at 3 hours post administration and at additional efficacy measurement timepoints of 4, 6, 12, 24 and 48 hours.
Read More
A Large Proportion of Medical Students Experience Migraines, Choose to Self-Manage Symptoms
September 1st 2022Though around 42% of medical students in study experience headaches, many of these causing significant functional disability, most choose to self-manage symptoms with sleep and medication.
Read More
Study to Evaluate Efficacy of Telehealth Cognitive Behavioral Therapy for Migraine
August 11th 2022Study will analyze whether cognitive behavioral therapy telehealth can lower headache days and disability as effectively as cognitive behavioral therapy plus a preventive medication for migraine.
Read More
Survey Finds Strong Link Between Migraine Symptoms and Mental Health
August 10th 2022Survey finds that 91% of health care providers and 67% of people with migraines feel that individuals who are able to successfully manage stress and mental health conditions can also better manage the symptoms of migraine.
Read More
Abortion Ban Could Be Life-Threatening for Women With Neurological Conditions
July 28th 2022Researchers highlight how a lack of access to medications used to treat multiple sclerosis, migraines, and epilepsy, but not proven safe for pregnancy, threatens child-bearing aged women who live with these conditions.
Read More
Vyepti Shows Positive Results in the Treatment of Migraine
June 28th 2022Investigators studied the efficacy and safety of eptinezumab-jjmr in the 100 mg and 300 mg intravenous infusion dosages in individuals with 2 to 4 documented unsuccessful prior preventive treatment failures for migraine in the past 10 years.
Read More